Abstract
Nonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia.
Highlights
Allogeneic stem cell transplantation is an effective treatment modality for acute myeloid leukemia (AML) that exerts its therapeutic benefit via a graft versus leukemia effect.[1]
Unlike our previous trial these cellular infusions occur without granulocyte colony stimulating factor (G-CSF) mobilization or preconditioning low-dose total body irradiation (TBI)
Peripheral blood samples were collected on days 2, 7 and 14 post-cellular infusion for short tandem repeat chimerism analysis
Summary
Blood Cancer Journal (2015) 5, e371; doi:10.1038/bcj.2015.100; published online 4 December 2015. Additional peripheral blood samples were collected pre-infusion as well as at 0–4, 8–24, 34–48, 72–96 and 168–192 h post infusion to evaluate recipient effector cells and cytokine release profiles. Recipient CD8 T cells demonstrated decreased perforin expression post infusion compared with pre-infusion with no changes in granzyme A/B, LAMP-1 or FasL expression. Recipient CD4 T cells showed increased LAMP-1 expression post infusion compared with pre-infusion with no changes in perforin, granzyme A/B or FasL expression. No changes in CTLA-4, OX40, 4–1BB and CD40L expression on recipient CD8 and CD4 T cells pre- or post infusion were observed. One of the five patients demonstrated a decrease in marrow blast counts post therapy (43% pre- to 21% 8 weeks post infusion). One patient is still alive with AML at 46 weeks post infusion This patient had stable disease following cellular infusion. Cytokine release profiles post infusion were consistent with an immune inhibitory profile with
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
